1672.HK Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 11:08):

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally...

Stats
Dzisiejszy wolumen	1.17M
Średni wolumen	885 204
Kapitalizacja rynkowa	1.43B
EPS	HKD0 ( 2023-08-22 )
Następna data zysków	( HKD0 ) 2024-05-23
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-9.47
ATR14	HKD0.00600 (0.42%)

Ascletis Pharma Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ascletis Pharma Inc Korelacja - Waluta/Towar

0.09
( neutral )

-0.24
( neutral )

0.00
( neutral )

-0.34
( neutral )

Ascletis Pharma Inc Finanse

Annual	2023
Przychody:	HKD56.60M
Zysk brutto:	HKD25.99M (45.92 %)
EPS:	HKD-0.130

FY	2023
Przychody:	HKD56.60M
Zysk brutto:	HKD25.99M (45.92 %)
EPS:	HKD-0.130

FY	2022
Przychody:	HKD54.09M
Zysk brutto:	HKD-24.69M (-45.65 %)
EPS:	HKD-0.340

FY	2021
Przychody:	HKD76.88M
Zysk brutto:	HKD39.17M (50.96 %)
EPS:	HKD-0.191

Financial Reports:

No articles found.

Ascletis Pharma Inc

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.